Sex-associated molecular differences for cancer immunotherapy

Youqiong Ye; Ying Jing; Liang Li; Gordon B. Mills; Lixia Diao; Hong Liu; Leng Han

doi:10.1038/s41467-020-15679-x

Nature Communications (Apr 2020)

Sex-associated molecular differences for cancer immunotherapy

Youqiong Ye,
Ying Jing,
Liang Li,
Gordon B. Mills,
Lixia Diao,
Hong Liu,
Leng Han

Affiliations

Youqiong Ye: Shanghai Institute of Immunology, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine
Ying Jing: Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School
Liang Li: Department of Biostatistics, The University of Texas MD Anderson Cancer Center
Gordon B. Mills: Knight Cancer Institute, Oregon Health and Science University
Lixia Diao: Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center
Hong Liu: Department of Dermatology, Xiangya Hospital, Central South University
Leng Han: Department of Biochemistry and Molecular Biology, The University of Texas Health Science Center at Houston McGovern Medical School

DOI: https://doi.org/10.1038/s41467-020-15679-x
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 8

Abstract

Read online

Immunotherapy has tremendous potential to treat many patients with cancer. In this study, the authors investigate the impact of gender on the response to therapy, highlighting the importance to include omics profiling in clinical studies.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal